Pre-diluted Allergen Kit System for Immunotherapy Access
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering allergens for immunotherapy are inefficient and costly, with subcutaneous injections being time-consuming and inaccessible to many, and allergens are not readily reimbursed due to lack of National Drug Code (NDC) inclusion in databases, leading to high healthcare and productivity costs.
Innovation Solution
A method for delivering allergens in pre-diluted kit form, involving a bulk container of antigen concentrate and sequential dilution with a carrier solution, providing a controlled and sterile environment for dilution, and packaging in single-dose containers for easy distribution and reimbursement through NDC association.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If subcutaneous injections are used for immunotherapy delivery, then the treatment can be administered, but the process becomes time-consuming and inaccessible to many patients
Solution Approach 1:
The patent segments the immunotherapy process into pre-diluted kits containing multiple sequential doses, allowing patients to self-administer at home rather than requiring repeated clinic visits for single injections
Solution Approach 2:
The patent performs preliminary dilution of antigens in controlled settings before patient use, creating ready-to-use kits that eliminate the need for patients to undergo time-consuming injection procedures at each visit
2Reliability
If allergens are not included in NDC databases, then traditional delivery methods can be used, but reimbursement becomes difficult and costs increase
Solution Approach 1:
The patent changes the parameter of allergen formulation from concentrated forms requiring complex preparation to pre-diluted forms with standardized concentrations that can be associated with NDC codes for reimbursement
Solution Approach 2:
The patent introduces pre-diluted kits as an intermediary form that bridges between concentrated allergens and final patient administration, enabling NDC association and reimbursement while simplifying the delivery process
3Productivity
If concentrated antigens are used, then storage and distribution are efficient, but preparation and administration become complex and costly
Solution Approach 1:
The patent performs preliminary dilution of concentrated antigens into pre-diluted kits with standardized concentrations, transferring the complexity from patient administration to controlled manufacturing processes
Solution Approach 2:
The patent uses disposable pre-diluted kits that eliminate the need for complex preparation equipment and sterilization processes at point of use, reducing preparation complexity and cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method simplifies the delivery of allergens, reduces costs, and facilitates reimbursement by providing a controlled and accessible form of immunotherapy, improving accessibility and reducing healthcare and productivity losses.
Implementation Method 1
providing a bulk container of base concentrate antigen containing at least one antigen at a predetermined concentrated level, providing a plurality of sequential bulk containers each containing a fixed amount of a carrier solution for diluting antigens
Data Source
AI summary
A method for delivering allergens to a pharmacist in a pre-diluted kit form, comprising providing a bulk container of base concentrate antigen containing at least one antigen at a predetermined concentrated level, creating a sequential and more diluted sequence of antigens, providing a plurality of end-use sealable containers that can receive a finite end amount of diluted antigens, dispensing from each of sequential bulk containers a finite end amount of diluted antigens into one of the plurality of end-use sealable containers, wherein the end-use seal containers filled from each of the sequential bulk containers comprises a group of end-use sealable containers associated with each of the sequential bulk containers, sealing each of the end-use containers after diluted antigens are disposed therein, and disposing a select number of the sealed end-use sealable containers from each of the groups of end-use sealable containers into a container comprising a kit.